EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Prothrombin complex concentrate for oral factor Xa inhibitor reversal prior to urgent invasive procedures

Mohammad Shamiea, Alex Osnis, Awan Kashoua, Orli Avnery, Gilad Itchaki, Shuli Isman, Tali Tohami, Osnat Jarchowsky-Dolberg, Martin Ellis iD

Transfusion · 2026-06 · 66 (6) · 1203-1209

DOI: 10.1111/trf.70197 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Transfusion, online erschienen am 02.04.2026. Verfasst von Mohammad Shamiea und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine A, Meir Medical Center, Kfar Saba, Israel. Hauptthemen laut MEDLINE: Blood Coagulation Factors, Factor Xa Inhibitors, Anticoagulation Reversal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Oral factor Xa (FXa) inhibitors are anticoagulants with no approved reversal agent for use before urgent invasive procedures. Four‐factor prothrombin complex concentrate (4F‐PCC) is used off‐label for this despite limited evidence regarding its effectiveness and safety.

Aims

To determine the efficacy of 4F‐PCC prior to urgent invasive procedures in FXa inhibitor‐treated patients. Secondary aims were hemoglobin levels and transfusion requirements within 48 h following the procedure, to determine the effect of treatment on anti‐FXa levels and to document thromboembolic events and mortality at 30 days.

Methods

We conducted a prospective, single‐center observational study of consecutive adults receiving 4F‐PCC for reversal of oral FXa inhibitors before urgent invasive procedures with moderate‐to‐high bleeding risk.

Results

Fifty‐nine were included in the analysis (median age 78 years). Apixaban was the most frequently used anticoagulant (83.1%). 74.6% underwent urgent surgical procedures and 25.4% underwent other invasive procedures. The median 4F‐PCC dose was 2000 units. The primary endpoint of normal or mildly abnormal hemostasis was achieved in 89.8% of patients (84.7% normal, 5.1% mildly abnormal). About 10.2% had moderately abnormal hemostasis; no patients had severe hemostatic failure. Median hemoglobin decline was 1.5 g/dL, with 8.5% of patients requiring red blood cell transfusion. In 17 patients with paired measurements, median decrease in anti‐FXa activity was 42%. Thromboembolic events occurred in 5.1%, and 30‐day mortality was 10.2%.

Conclusions

Thromboembolic events were infrequent. These data support the use of 4F‐PCC for reversal of FXa inhibitors prior to urgent invasive procedures with a moderate or high bleeding risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood Coagulation FactorsFactor Xa InhibitorsAnticoagulation ReversalHumansFemaleAgedMaleAged, 80 and overProspective StudiesMiddle AgedHemorrhageAdministration, OralThromboembolismPyridones

Stichwörter der Autor:innen

factor Xa inhibitor reversalhemostatic efficacyprothrombin complex concentrate

Substanzen

prothrombin complex concentratesBlood Coagulation FactorsFactor Xa InhibitorsPyridones

Autor:innen und Institutionen

  • Department of Medicine A, Meir Medical Center, Kfar Saba, Israel.
  • Blood Bank, Meir Medical Center, Kfar Saba, Israel.
  • Hematology Institute, Meir Medical Center, Kfar Saba, Israel.
  • Gray Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  • Coagulation Laboratory, Meir Medical Center, Kfar Saba, Israel.

ORCID-Profile: Martin Ellis

Zitieren

APA

Shamiea, M., Osnis, A., Kashoua, A., Avnery, O., Itchaki, G., Isman, S., Tohami, T., Jarchowsky-Dolberg, O., & Ellis, M. (2026). Prothrombin complex concentrate for oral factor Xa inhibitor reversal prior to urgent invasive procedures. Transfusion, 66(6), 1203-1209. https://doi.org/10.1111/trf.70197

Vancouver

Shamiea M, Osnis A, Kashoua A, Avnery O, Itchaki G, Isman S, et al. Prothrombin complex concentrate for oral factor Xa inhibitor reversal prior to urgent invasive procedures. Transfusion. 2026;66(6):1203-1209. doi:10.1111/trf.70197

BibTeX
@article{Shamiea2026,
  author = {Shamiea, Mohammad and Osnis, Alex and Kashoua, Awan and Avnery, Orli and Itchaki, Gilad and Isman, Shuli and Tohami, Tali and Jarchowsky-Dolberg, Osnat and Ellis, Martin},
  title = {Prothrombin complex concentrate for oral factor Xa inhibitor reversal prior to urgent invasive procedures},
  journal = {Transfusion},
  year = {2026},
  volume = {66},
  number = {6},
  pages = {1203--1209},
  doi = {10.1111/trf.70197}
}
Kostenlos starten →